Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 19/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 18/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 6/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576190 | 0.91 | FLT3 (0.51) | FLT3CHEK1KITMAP3K7RPS6KB1 | |
| SCHEMBL12478740 | 0.83 | PTK2 (0.53) | PTK2 | |
| SCHEMBL15524693 | 0.83 | JAK3 (0.45) | FLT3PTK2KIT | |
| SCHEMBL12478690 | 0.82 | PTK2 (0.53) | PTK2PRKAG1PRKAA2PRKAB1 | |
| SCHEMBL15524830 | 0.82 | PTK2 (0.49) | PTK2 | |
| SCHEMBL12478260 | 0.81 | PTK2 (0.54) | PTK2 | |
| SCHEMBL15524488 | 0.81 | PTK2 (0.45) | PTK2 | |
| SCHEMBL15524833 | 0.81 | PTK2 (0.44) | FLT3PTK2KIT | |
| SCHEMBL15524349 | 0.80 | FLT4 (0.52) | FLT3PTK2KIT | |
| SCHEMBL12479026 | 0.80 | PTK2 (0.51) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675793-B1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| US-20130324532-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | FLT3 82/4885CHEK1 232/4885PTK2 1/4885 |
| US-20130324532-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | FLT3 82/4885CHEK1 232/4885PTK2 1/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | FLT3 238/4885CHEK1 206/4885PTK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.